Ocular Therapeutix - צמיחת מכירות משנה לשנה (TTM) OCUL

Ocular Therapeutix (OCUL) operates a recession-resistant business, as its success depends on the implementation of ophthalmological implants and new drug testing. The percentage change in sales over the last 12 months compared to the previous 12 months visualizes revenue dynamics, where -9.50 characterizes this valuation parameter. Growth is supported by proprietary hydrogels and the complexities of physician training, as well as optimized logistics for specialized pharmaceuticals, ensuring high profitability.
Ocular Therapeutix, Inc. - פילוחים אנליטיים ומדדי מפתח (OCUL)

This indicator is critical for stress-testing business scaling rates during stock selection. It measures the daily revenue growth over a rolling year, reflecting the current market valuation through the discounting of future cash flows. By analyzing year-over-year sales dynamics using the TTM methodology, an investor sees the value of -9.50. For Ocular Therapeutix (OCUL), this growth confirms the effective commercialization of innovative gel implants across various ophthalmology segments.